Free shipping on all orders over $ 500

Glepaglutide

Cat. No. M31345
Glepaglutide Structure
Size Price Availability Quantity
5mg USD 320  USD320 In stock
10mg USD 550  USD550 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Glepaglutide is a novel, long-acting glucagon-like peptide-2 (GLP-2) analog and a potent GLP-2R agonist. Glepaglutide is used in studies related to inflammatory bowel disease (IBD) and Crohn's disease.

Chemical Information
Molecular Weight 4316
Formula C197H325N53O55
CAS Number 914009-86-2
Form Solid
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Jolanta Skarbaliene, et al. BMC Gastroenterol. Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats

[2] Mikkel Askjær Agersnap, et al. Clin Pharmacokinet. Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment

[3] Mikkel Askjær Agersnap, et al. Clin Drug Investig. Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects

[4] Rahim M Naimi, et al. JPEN J Parenter Enteral Nutr. Effects of glepaglutide, a long-acting glucagon-like peptide-2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phase 2 trial

[5] Rahim M Naimi, et al. Lancet Gastroenterol Hepatol. Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial

Related GLP Receptor Products
Amycretin

Amycretin is a novel, potentially first-in-class, long-acting co-agonist of GLP-1 and the amyloid receptor (AMYR) for obesity-related studies.

NM-003

NM-003 is a GLP-2R agonist that can be used in studies related to inflammatory bowel disease.

NB-1002

NB-1002 is a GLP-2R agonist that can be used in studies related to short bowel syndrome.

MOD-15014

MOD-15014 is a GLP-2R modulator that can be used in studies related to short bowel syndrome.

HM-15912

HM-15912 is a GLP-2R agonist that can be used in studies related to short bowel syndrome.

  Catalog
Abmole Inhibitor Catalog




Keywords: Glepaglutide supplier, GLP Receptor, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.